secwatch.observer — SEC 8-K summary
======================================

Issuer:     Benitec Biopharma Inc. (BNTC)
CIK:        0001808898
Form:       8-K
Filed at:   2023-06-26T23:59:59+00:00
Accession:  0001193125-23-174479
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Benitec Biopharma receives FDA IND clearance for BB-301 gene therapy for OPMD
-----------------------------------------------------------------------------

- FDA cleared IND for BB-301, a silence-and-replace gene therapy for Oculopharyngeal Muscular Dystrophy (OPMD).
- OPMD affects ~15,000 patients in US, Canada, Western Europe, and Israel; no approved therapies currently.
- First subject dosing expected in H2 2023 after rollover from ongoing Natural History study (13 subjects enrolled).
- Interim safety and efficacy data from Phase 1b/2a study to be reported every ~90 days post-dosing.
- BB-301 designed to treat OPMD-related dysphagia, a life-threatening swallowing disorder.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808898/000119312523174479/0001193125-23-174479-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808898/000119312523174479/d516975d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-174479

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer